Atrial Fibrillation Trial, Recruiting NCT05900414 Sponsor: University of Calgary Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT05900414
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with atrial fibrillation (an irregular heartbeat) that is not caused by a heart valve problem, within the last 12 months, at any level of stroke risk.
  • People who are 18 years of age or older.
  • People who are either not currently taking blood-thinning medication (oral anticoagulants), or who have been taking it for fewer than 90 days.
  • People who have a first appointment with a specialist about their atrial fibrillation scheduled to occur within 7 to 30 days.

Who may not be able to join:

  • People whose atrial fibrillation is linked to a mechanical heart valve, a condition called rheumatic mitral stenosis, or moderate to severe non-rheumatic mitral stenosis (a narrowing of a heart valve not caused by rheumatic fever).
  • People who are currently prescribed two types of blood-thinning tablets together (such as aspirin combined with clopidogrel, ticagrelor, or prasugrel) for a reason unrelated to their irregular heartbeat.
  • People who need to take blood-thinning medication for a reason other than their atrial fibrillation.
  • People who have a permanent barrier to using online tools, such as no access to the internet or difficulty reading English at around a Grade 5 level (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stephen B Wilton, MD, University of Calgary

Phone: 403-210-7102

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Calgary
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
1 October 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

The 9-Item Shared Decision Making Questionnaire (SDM-Q-9: patient version).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov